XML 79 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Shareholders' Equity (Details) - USD ($)
 12 Months Ended
Dec. 15, 2022
May 02, 2022
Jan. 04, 2021
Dec. 16, 2020
May 16, 2019
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 14, 2022
Dec. 15, 2020
Feb. 19, 2020
Shareholders' Equity (Details) [Line Items]                      
Issuance of ordinary shares     800,000   400,000            
Shares issued, price per share (in Dollars per share)         $ 2.5            
Gross proceeds (in Dollars)     $ 2,000,000   $ 1,000,000            
Issuance of expenses (in Dollars)     $ 1,841,000   $ 65,000            
Issued of warrants     720,000   240,000            
Exercise price (in Dollars per share)     $ 2.75   $ 3.3            
Warrant, description           The warrants were exercisable for 3.5 years and were subject to a three-year vesting period as follows: one third of the warrants shall vest annually (upon the lapse of 12 months, 24 months and 36 months from issuance), provided that on the applicable vesting date the investor did not sell any of the Ordinary Shares purchased in the private placement. Vesting of all of the warrants was to be accelerated in the event that any one or more shareholders acting together acquire a block of 40% of the Company’s issued and outstanding share capital. In addition, the Company issued 60,000 warrants as fees to a placement agent.          
Purchase price per shares (in Dollars per share)     $ 2.5                
Increase of ordinary shares 3,000,000     2,000,000              
Ordinary shares, shares authorized 11,000,000     6,000,000   11,000,000 11,000,000   8,000,000 8,000,000  
Ordinary shares   450,000                  
Purchase price per shares (in Dollars per share)   $ 2.2                  
Exercise price per shares (in Dollars per share)   $ 2.2                  
Total amount (in Dollars)   $ 990,000                  
Net issuance expenses (in Dollars)   911,000                  
Issued of warrants (in Dollars)   $ 8,100                  
Share based compensation options description           Each option granted under the Plan expires five years from the date of the grant.          
Capital gain tax rate           25.00%          
Exercisable annual period           3 years          
Vesting period           3 years          
Share-based compensation expense (in Dollars)           $ 98,000 $ 97,000 $ 67,000      
Intrinsic value of options (in Dollars)           $ 0 $ 0 $ 70,000      
Minimum [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Issuance of ordinary shares 300,000                    
Maximum [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Issuance of ordinary shares 1,000,000                    
Stock Option [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Share based compensation options description           In May 2003, the Company’s shareholders approved the adoption of the 2003 Israeli Stock Option Plan or the Plan. In December 2012, the Company’s shareholders approved a 10 year extension to the Plan, according to which the Board of Directors may grant options under the Plan through May 31, 2023. In December 2017, the shareholders approved an increase of the pool of shares reserved for issuances under the Plan, to 500,000 Ordinary Shares. In July 18, 2018, the Company’s shareholders approved (i) an increase of the number of Ordinary Shares available for issuance under the Plan, by 200,000 to a total of 700,000 Ordinary Shares, and (ii) an amendment of the Plan allowing for the grant of Ordinary Shares in addition to options.          
Options available for future grants           285,284          
Weighted-average grant-date fair value of options granted (in Dollars per share)           $ 0 $ 0.82 $ 1.2      
Weighted-average grant-date fair value of unvested options (in Dollars per share)           $ 0.97          
Options exercised           46,500 1,000 52,167      
Non-vested share-based compensation (in Dollars)           $ 93,000 $ 191,000        
YA II [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Debt instrument, description           The loan was paid in 12 monthly installments of principal and interest starting from March 2020 throughout 2021. BOS issued to YA II warrants to purchase up to 100,000 Ordinary Shares of the Company at an exercise price of $3.00 per Ordinary Share. The Company allocated on amount of $30 with respect to such warrants under “additional paid in capital” and as a discount on the loan. The discount was reflected as financing expenses over the term of the loan. As of December 31, 2021 the entire balance of the loan was repaid. The warrants were exercisable for a period of two years from issuance and on February 19, 2022, expired without being exercised.          
Directors and Officers [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Ordinary shares issued               175,000      
Directors and Officers [Member] | YA [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Ordinary shares issued             87,500        
Directors and Officers [Member] | Ordinary Shares [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Ordinary shares issued             87,500        
CEO, Eyal Cohen [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Ordinary shares issued 80,000                    
Ziv Dekel [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Ordinary shares issued 7,500                    
Ruby Tech Inc [Member] | YA II [Member]                      
Shareholders' Equity (Details) [Line Items]                      
Principal amount (in Dollars)                     $ 600,000,000
Interest rate                     8.00%